Research programme: tyrosine kinase inhibitors - Concentra Biosciences
Latest Information Update: 28 May 2025
At a glance
- Originator Theseus Pharmaceuticals
 - Developer Concentra Biosciences
 - Class Antineoplastics; Small molecules
 - Mechanism of Action Protein tyrosine kinase inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- No development reported Gastrointestinal cancer
 
Most Recent Events
- 28 May 2025 No recent reports of development identified for research development in Gastrointestinal-cancer in USA
 - 13 Jul 2023 Theseus Pharmaceuticals expects to nominate lead candidate from the programme in the first half of 2024
 - 04 Apr 2022 Vipergen establishes DNA Encoded Library (DEL)- based drug discovery partnership with Theseus Pharmaceuticals to develop small-molecule compounds for Cancer